Arizona Liver Health - Tucson
Arizona Liver Health - Tucson
Tucson, Arizona, United States8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-10-09 | NCT07288138 | |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-10-08 | NCT05519475 | |
| A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Phase 2 | 2026-10-01 | NCT07112872 | |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Metabolic Dysfunction Associated Steatohepatitis | Recruiting | Phase 3 | 2026-10-01 | NCT06632457 | |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder | Recruiting | Phase 3 | 2026-10-01 | NCT06632444 | |
| A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-09-29 | NCT07527910 | |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder, metabolic dysfunction-associated steatohepatitis | Active, not recruiting | Phase 3 | 2026-07-08 | NCT05500222 | |
| A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | Phase 2 | 2026-05-18 | NCT07491458 |